Edwards Lifesciences Q4 2024 beats estimates, stock surges
Shares of Edwards Lifesciences Corp. rallied 6.92% to $75.82 Wednesday, on what proved to be an all-around grim trading ...
Edwards Lifesciences (NYSE:EW – Get Free Report) had its price objective upped by Morgan Stanley from $70.00 to $75.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an ...
Canaccord raised the firm’s price target on Edwards Lifesciences (EW) to $71 from $66 and keeps a Hold rating on the shares. The firm said they ...
Women are often underdiagnosed and undertreated when it comes to heart disease, particularly conditions like aortic stenosis.
Edwards Lifesciences beat Q4 estimates with $1.39B in sales, driven by growth in TMTT, TAVR, and Surgical. The company ...
Morgan Stanley raised the firm’s price target on Edwards Lifesciences (EW) to $75 from $70 and keeps an Equal Weight rating on the shares.
Edwards Lifesciences had a higher profit and sales in its fourth quarter as demand for its products held strong. The medical-technology company posted a profit of $385.6 million, or 65 cents a share, ...
Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat. On Tuesday, Edwards Lifesciences (NYSE:EW) reported fourth-quarter sales ...
Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback